Pricing biologics: Issues, strategic priorities and a conceptual model
Tóm tắt
The advent of complex and often expensive biologics raises critical commercial challenges – the most important of which pertains to developing a viable pricing, distribution and reimbursement model that is intrinsically geared to the special characteristics of biologic products and the expectations of a diverse customer population. Idiosyncratic differences in health-care systems, their philosophical motivations and preferred methods of controlling access to expensive biologic treatments pose additional challenges. This article discusses key issues about pricing biologics from the primary viewpoint of biologic manufacturers and marketers, focusing on the inseparable relationship between price, distribution, access and reimbursement. Specific priorities are explicated for streamlining biologic pricing and access strategies to meet upcoming challenges. A conceptual model for developing viable biologic pricing strategy is presented. Insights from the author's work implementing key aspects of the model in the real world are discussed. The article concludes by presenting an overview of a pricing decision support system that has proven invaluable in formulating and managing biologic pricing strategies over a finite time horizon.
Tài liệu tham khảo
Rao, S.K. (2010) Rethinking commercial strategy – A patient-centered commercial model. Journal of Commercial Biotechnology 16 (3): 206–223.
Van Brunt, J. (2010) Biotech drug approvals – A year of firsts. Signals, Published 9 February 2010, also accessed online on 22 July 2010.
CVS Caremark, Evolving Pharmacy Care, © 2010 by CVS Caremark.
Cowen & Co. (2007) Therapeutic Categories Outlook. New York: Cowen & Company LLC.
NCPIE. (2007) Prescription medicine adherence, a national action plan. Compliance & Persistence With Medication Therapy, Special Supplement to Managed Care. 9 (9).
INSIGHTS. (2010) Evolving pharmacy care for improved outcomes & lower costs. p. 26, INSIGHTS, Evolving Pharmacy Care, CVS Caremark.
Silverman, E. (2005) Biologics looming price tag has payers retooling pharmacy coverage. Biotechnology Healthcare, April: 35–42.
Kaiser/HRET Employer Health Benefits 2007 Annual Survey.
Goodman, C.S. (2004) HTA 101, Introduction to Health Technology Assessment. Falls Church, VA: The Lewin Group.
Okon, T., Coplon, S. and Kube, D. (2004) Problems facing cancer care with Medicare's definition of average selling price. Community Oncology 1 (1): 59–63.
Mullen, P. (2007) The arrival of ASP. Biotechnology Healthcare, June 2007.
Taylor, L. (2010) Drug makers slam German price moves. PharmaTimes, 1 April 2010.
Taylor, L. (2010) QALYs are an industry trick says German health chief. PharmaTimes, 7 April 2010.
Rao, S.K. (2009) A new paradigm for developing bio/pharmaceutical positioning strategy. Journal of Medical Marketing 9 (1): 29–39.
Miller, G. (2010) Expert tips for REMS success. FiercePharma Manufacturing, 14 May 2010, http://www.fiercepharmamanufacturing.com/special-reports/expert-tips-rems-success?source=FBpusher#ixzz0xSCQicmk, accessed 23 August 2010.
Prescription Medicine Adherence, A National Action Plan, NCPIE, August 2007.
Somers, T. (2010) Path sought for generic biologic drugs – Manufactured proteins can’t be copied exactly. News, www.signonsandiego.com, accessed 1 September 2010.
Sherman, C. (2010) Out-of-pocket costs put arthritis drugs out of reach for some. Health Behavior News Service, 20 May 2010.
Rao, S.K. (2006) Rising to the challenge. SCRIP, March 2006; www.scripmag.com, pp. 18–21.
Bradbury, K. (2009) Specialty drugs – Rich pipeline that needs to be managed. Biotechnology Healthcare, October–November: 35–40.
Heitzman, L., Shapurji, D., Poulin, M. and Lesser, N. (2009) What Payers Want, Viewing Payers as Customers. Deloitte Life Sciences, Deloitte Development LLC.
Rao, S.K. (2010) Enabling bio/pharmaceutical pricing strategies by integration across customers & constructs. Presentation, European Pharmaceutical Marketing Research Association, Berlin, June 2010.
Rao, S.K. (2008) Market access: An innovative to developing & managing bio/pharmaceutical pricing strategy. Journal of Medical Marketing 8 (2): 94–100.
Rao, S.K. (2000) Marketing decision support systems for strategy building. Marketing Health Services, AMA, Summer 2000.